Stockscreener 앱 받기
37.50
6.69%
-2.69
시간 외 거래:
37.80
0.30
+0.80%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awards - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cytokinetics Leadership Takes Center Stage at Elite Needham Healthcare Conference - Stock Titan
Cytokinetics stock hits 52-week low at $40.49 amid market challenges - Investing.com UK
Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - MarketScreener
Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN
Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times
Groundbreaking Healthcare Tool Unlocks Insights from 65,000 Pharmacies' HCM Data - Stock Titan
Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $87,160 in stock - Investing.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - MarketScreener
Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan
H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK
Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView
Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma
UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com
Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK
Cytokinetics’ EVP sells $4,500 in stock - Investing.com India
Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa
Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com India
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
3.89%
0.13%
자본화:
|
볼륨(24시간):